Post-earnings recap
Reported
Thu, Mar 12, 2026
EPS actual
$-0.15
EPS est.
$-0.14
EPS surprise
-11.11%
1-day move
-5.27%
Est. EPS
—
Est. Rev
—
Impl. Move
—
Corvus Pharmaceuticals reported a loss of $0.15 per share, which was worse than expected. The stock reacted negatively, declining by 5.27%. Investors may be concerned about the lack of revenue details and any future guidance, which could indicate uncertainty about the company's financial health.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.15 | N/A | -11.11% |
| Revenue | N/A | N/A | N/A |
No transcript is on record for this earnings call, and the analysis is based solely on numerical results.